Azapropazone
![]() | |
![]() | |
| Systematic (IUPAC) name | |
|---|---|
|
(RS)-5-(Dimethylamino)-9-methyl-2-propyl-1H-pyrazolo[1,2-a][1,2,4]benzotriazine-1,3(2H)-dione | |
| Clinical data | |
| Trade names | Rheumox |
| AHFS/Drugs.com | International Drug Names |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Biological half-life | 20 hours |
| Identifiers | |
| CAS Number |
13539-59-8 |
| ATC code | M01AX04 (WHO) |
| PubChem | CID 26098 |
| ChemSpider |
24310 |
| UNII |
K2VOT966ZI |
| KEGG |
D02966 |
| ChEBI |
CHEBI:38010 |
| ChEMBL |
CHEMBL1231131 |
| Chemical data | |
| Formula | C16H20N4O2 |
| Molar mass | 300.36 g/mol |
| Chirality | Racemic mixture |
| |
| |
| | |
Azapropazone is a non-steroidal anti-inflammatory drug. It is manufactured by Goldshield under the tradename Rheumox.[1]
It was available in the UK as a prescription-only drug, with restrictions due to certain contra-indications and side-effects.[2] Azopropazone has now been discontinued in the British National Formulary.
Azapropazone has a half-life of approximately 20 hours in humans and is not extensively metabolized.[3]
References
- ↑ http://home.intekom.com/pharm/cont_eth/rheumox.html
- ↑ http://www.patient.co.uk/showdoc/30002267/
- ↑ Jones CJ (1976). "The pharmacology and pharmacokinetics of azapropazone - a review". Curr Med Res Opin 4 (1): 3–16. doi:10.1185/03007997609109361. PMID 770078.
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Tuesday, April 19, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.

